This COVID Giant's Shares Are Lagging Behind Rivals -- Here's Why

Pfizer (NYSE: PFE) won the world's most-watched race when it scored the first emergency authorization for a COVID-19 vaccine. The U.K. gave Pfizer and partner BioNTech the nod in early December. And the U.S. and other countries followed soon afterward. Moderna's vaccine also entered the market in December.

But there's more to Pfizer's coronavirus story. This past week, Pfizer said it has launched a phase 1 trial of an oral antiviral treatment for COVID-19. The big pharma company also is studying an intravenously administered therapeutic in a phase 1b trial.

Pfizer may be on its way to becoming a coronavirus powerhouse. Yet it's share price hasn't followed. Let's take a closer look.

Continue reading

Source Fool.com